Therapeutic effects of cetraxate against acute gastritis and acute aggravation of chronic gastritis. Endoscopic investigation by the double-blind method.
To determine the efficacy of cetraxate against acute gastritis and acute aggravation of chronic gastritis, a comparison was made with aldioxa as the standard drug by the double-blind method based mainly on observations by gastroscopy. There were four types of gastroscopic findings used: hemorrhage, erosion, redness and edema. Observations were performed whenever possible before and 1, 2 and 4 weeks after administration, and the cure and improvement rates were investigated. The cure rates for each finding except edema after 1 and 2 weeks were better (in the order of redness, erosion and hemorrhages) in the cetraxate group than in the aldioxa group, and there was a significant difference for redness in the 1st week (p less than 0.05). The no change and aggravating rates were also lower for redness in the 1st week (p less than 0.05) and edema in the 1st week (p less than 0.10) in the cetraxate group than in the aldioxa group. There were almost no differences in the effects of both drugs on subjective symptoms. The safety based on type and incidence of side effects was considered to be high for both drugs. From these results, it appeared that cetraxate is effective against acute gastritis and acute aggravation of chronic gastritis.
D000208:Acute Disease; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005756:Gastritis / Q000188:drug therapy*; D005773:Gastroscopy; D006801:Humans; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D003509:Cyclohexanecarboxylic Acids; C000665:cetraxate; D014148:Tranexamic Acid